MAYWOOD, IL – Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.
Patrick Stiff, MD, director of Loyola's Cardinal Bernardin Cancer Center, is a co-author of the study, published December 10, 2017 in the New England Journal of Medicine. The treatment used in the study, which involves a cell therapy called CAR T, is offered by Kite Pharma. Two other companies, Novartis and Juno Therapeutics, also are developing CAR T-cell cancer treatments.
Dr. Stiff said Loyola is preparing to offer the treatment early next year to carefully selected lymphoma patients who have failed earlier treatments. He cautioned that while the therapy could potentially cure patients who have run out of other options, it also can cause severe side effects. The cost of the treatment is also considerable to patients. Dr. Stiff said Loyola would carefully inform patients of the pros and cons of this new therapy if it is presented as an option.
"We are taking a very measured approach to this new therapy, which is effective, but also potentially toxic," Dr. Stiff said. "The therapy should not be considered a cure-all, since some of the patients did relapse after the therapy."
Based on results of the study, the Food and Drug Administration approved a CAR T treatment called Yescarta. The study included 111 patients from 22 centers, including Loyola. The patients had certain types of large B-cell lymphoma and had not responded to or had relapsed after undergoing at least two other treatments, including chemotherapy and stem cell transplants.
To fight the cancer, the treatment harnesses a patient's T-cells (white blood cells that are part of the immune system). T-cells are collected from the patient and sent to a lab. There, the cells are genetically modified to include a gene that instructs the cells to target and kill lymphoma cells. Millions of these genetically modified T-cells then are infused back into the patient.
In the study, 42% of patients who underwent the CAR T treatment were in complete remission after a median follow-up of 15.4 months. "This is impressive, since most patients had exhausted all other care options," Dr. Stiff said.
Details in the report included that 95% of patients experienced at least one side effect that was severe. Thirteen percent experienced life-threatening cytokine release syndrome (CRS), which can cause high fever and flu-like symptoms, and 28% of patients experienced neurologic problems including encephalopathy (diseased brain), 21%; confused state, 9%; aphasia (difficulty communicating), 7%; and somnolence (excessive sleepiness), 7%. Other side effects included coma, serious infections, low blood cell counts and weakened immune systems.
The study found that the incidence of CRS and severe neurologic problems decreased over the course of the study, possibly due to the centers gaining more experience and this trend has continued.
Dr. Stiff said Loyola's participation in the clinical trial, along with its extensive experience in treating patients with lymphoma and other blood cancers, will help in providing the safest possible CAR T treatments.
"We are developing a system to treat carefully selected patients who might benefit from the therapy with a maximum of benefits and a minimum of toxicities," he said.
The cure rate in the CAR T study was similar to the approximate 45% cure rate from an allogeneic bone marrow transplant. In this well-established treatment, healthy stem cells obtained from a donor's bone marrow are infused into the patient.
"Centers such as Loyola, which have expertise in both therapies, now will be able to offer additional treatment options to produce long-term remissions and cures in patients with advanced lymphomas," Dr. Stiff said.
The study is titled "Axicagagene Ciloleucel (CD19 CAR T) in Refractory Large B-Cell Lymphoma."
The study was led by Sattva Neelapu, MD, of the MD Anderson Cancer Center and Frederick Locke, MD, of the H. Lee Moffitt Cancer Center and Research Institute.
About Loyola Medicine
Loyola Medicine, a member of Trinity Health, is a nationally ranked academic, quaternary care system based in Chicago's western suburbs. The three-hospital system includes Loyola University Medical Center (LUMC), Gottlieb Memorial Hospital, MacNeal Hospital, as well as convenient locations offering primary care, specialty care and immediate care services from nearly 2,000 physicians throughout Cook, Will and DuPage counties. LUMC is a 547-licensed-bed hospital in Maywood that includes the William G. and Mary A. Ryan Center for Heart & Vascular Medicine, the Cardinal Bernardin Cancer Center, the John L. Keeley, MD, Emergency Department, a Level 1 trauma center, Illinois's largest burn center, the Nancy W. Knowles Orthopaedic Institute, a certified comprehensive stroke center, transplant center and a children’s hospital. Having delivered compassionate care for over 50 years, Loyola also trains the next generation of caregivers through its academic affiliation with Loyola University Chicago’s Stritch School of Medicine and Marcella Niehoff School of Nursing.
Established in 1961, Gottlieb Memorial Hospital is a 247-licensed-bed community hospital in Melrose Park that includes the Judd A. Weinberg Emergency Department, the Loyola Center for Metabolic Surgery and Bariatric Care, Loyola Cancer Care & Research at the Marjorie G. Weinberg Cancer Center, acute rehabilitation, a transitional care center, childcare center and fitness center. MacNeal Hospital is a 374-licensed-bed teaching hospital in Berwyn with advanced medical, surgical and psychiatric services and a 68-bed behavioral health program.
For more information, visit loyolamedicine.org. You can also follow Loyola Medicine on LinkedIn, Facebook, Instagram or X (formerly known as Twitter).
About Trinity Health
Trinity Health is one of the largest not-for-profit, faith-based health care systems in the nation. It is a family of 127,000 colleagues and more than 38,300 physicians and clinicians caring for diverse communities across 26 states. Nationally recognized for care and experience, the Trinity Health system includes 93 hospitals, 107 continuing care locations, the second largest PACE program in the country, 142 urgent care locations and many other health and well-being services. In fiscal year 2024, the Livonia, Michigan-based health system invested $1.3 billion in its communities in the form of charity care and other community benefit programs. For more information, visit us at www.trinity-health.org, or follow us on LinkedIn, Facebook, and X (formerly known as Twitter).